Search research articles
Contact Us
Filters
Showing results (11-20 of 69) with videos related to
Page
of 7
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 24, 2002
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information
Neil Parkin, Colombe Chappey, Laura Maroldo, et al.
Viruses
|
May 24, 2020
External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations
Hezhao Ji, Neil Parkin, Feng Gao, et al.
Journal of Clinical Microbiology
|
December 16, 2011
Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay
Miguel Arredondo, Carolina Garrido, Neil Parkin, et al.
Viruses
|
June 11, 2020
Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations
Santiago Ávila-Ríos, Neil Parkin, Ronald Swanstrom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 1, 2012
Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network
Neil Parkin, Carmen de Mendoza, Rob Schuurman, et al.
Journal of Clinical Microbiology
|
January 17, 2014
Sequence conservation of the region targeted by the Abbott RealTime HCV viral load assay
Gavin Cloherty, Neil Parkin, James Rhoads, et al.
Antimicrobial Agents and Chemotherapy
|
November 15, 2006
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication
Hongmei Mo, Neil Parkin, Kent D Stewart, et al.
AIDS Research and Human Retroviruses
|
September 16, 2011
Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase
Allison K Delong, Mingham Wu, Diane Bennett, et al.
Open Forum Infectious Diseases
|
March 24, 2026
Re-evaluating the Potential Impact of Preexposure Prophylaxis (PrEP) in Achieving HIV Elimination in the United States: Insights From Modeling
Jason Baron, Tamar Tchelidze, Neil Parkin, et al.
AIDS (London, England)
|
March 5, 2008
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes
Eva Poveda, Carmen de Mendoza, Neil Parkin, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 69) with videos related to
Sort By:
Page
of 7
Journal of Acquired Immune Deficiency Syndromes (1999)
|
October 24, 2002
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information
Neil Parkin, Colombe Chappey, Laura Maroldo, et al.
Viruses
|
May 24, 2020
External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations
Hezhao Ji, Neil Parkin, Feng Gao, et al.
Journal of Clinical Microbiology
|
December 16, 2011
Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay
Miguel Arredondo, Carolina Garrido, Neil Parkin, et al.
Viruses
|
June 11, 2020
Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations
Santiago Ávila-Ríos, Neil Parkin, Ronald Swanstrom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 1, 2012
Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network
Neil Parkin, Carmen de Mendoza, Rob Schuurman, et al.
Journal of Clinical Microbiology
|
January 17, 2014
Sequence conservation of the region targeted by the Abbott RealTime HCV viral load assay
Gavin Cloherty, Neil Parkin, James Rhoads, et al.
Antimicrobial Agents and Chemotherapy
|
November 15, 2006
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication
Hongmei Mo, Neil Parkin, Kent D Stewart, et al.
AIDS Research and Human Retroviruses
|
September 16, 2011
Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase
Allison K Delong, Mingham Wu, Diane Bennett, et al.
Open Forum Infectious Diseases
|
March 24, 2026
Re-evaluating the Potential Impact of Preexposure Prophylaxis (PrEP) in Achieving HIV Elimination in the United States: Insights From Modeling
Jason Baron, Tamar Tchelidze, Neil Parkin, et al.
AIDS (London, England)
|
March 5, 2008
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes
Eva Poveda, Carmen de Mendoza, Neil Parkin, et al.
Page
of 7